The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.
Boris J. N. Winterhoff
No relevant relationships to disclose
Stefan Kommoss
No relevant relationships to disclose
Ann L. Oberg
No relevant relationships to disclose
Chen Wang
No relevant relationships to disclose
Shaun M. Riska
No relevant relationships to disclose
Gottfried E. Konecny
No relevant relationships to disclose
Jian-Bing Fan
Employment or Leadership Position - Illumina
Viji Shridhar
No relevant relationships to disclose
Ellen L. Goode
No relevant relationships to disclose
Friedrich Kommoss
No relevant relationships to disclose
Andreas Du Bois
No relevant relationships to disclose
Felix Hilpert
No relevant relationships to disclose
Jeremy Chien
No relevant relationships to disclose
Andrew Christopher Embleton
No relevant relationships to disclose
Mahesh Parmar
No relevant relationships to disclose
Richard S. Kaplan
No relevant relationships to disclose
Timothy Perren
No relevant relationships to disclose
Lynn C. Hartmann
No relevant relationships to disclose
Jacobus Pfisterer
No relevant relationships to disclose
Sean Christopher Dowdy
No relevant relationships to disclose